Science Links Japan | Comparison of 1-week and 2-week triple therapy with omeprazole, amoxicillin, and clarithromycin in peptic ulcer patients with Helicobacter pylori infection. Results of a randomized controlled trial.

Comparison of 1-week and 2-week triple therapy with omeprazole, amoxicillin, and clarithromycin in peptic ulcer patients with Helicobacter pylori infection. Results of a randomized controlled trial.

Accession number;00A0234932

Title;Comparison of 1-week and 2-week triple therapy with omeprazole, amoxicillin, and clarithromycin in peptic ulcer patients with Helicobacter pylori infection. Results of a randomized controlled trial.

Author; KIYOTA K (Saiseikai Noe Hospital, Osaka, Jpn) HABU Y (Saiseikai Noe Hospital, Osaka, Jpn) SUGANO Y (Saiseikai Noe Hospital, Osaka, Jpn) INOKUCHI H (Saiseikai Noe Hospital, Osaka, Jpn) MIZUNO S (General Railway Hospital Of Osaka, Osaka, Jpn) KIMOTO K (General Railway Hospital Of Osaka, Osaka, Jpn) KAWAI K (General Railway Hospital Of Osaka, Osaka, Jpn)

Journal Title;J Gastroenterol

Journal Code:Z0748A

ISSN:0944-1174

VOL.34;NO.Supplement 11;PAGE.76-79(1999)

Figure&Table&Reference;TBL.3, REF.12

Pub. Country;Japan

Language;English

Abstract;This study was a comparison of 1-week and 2-week triple therapies with omeprazole, amoxicillin, and clarithromycin (OAC) in patients with peptic ulcer disease and Helicobacter pylori infection. A total of 147 peptic ulcer patients with H. pylori infection assessed by histology and culture were randomly treated with omeprazole 20 mg bid + amoxicillin 1000 mg bid + clarithromycin 400 mg bid for either 1 week (OAC1w) or 2 weeks (OAC2w). Both groups then received omeprazole 20mg daily for 2 weeks followed by ranitidine 300 mg daily for 4 weeks. Eradication of H. pylori was assessed by histology, culture, and the '13'C-urea breath test ('13'C-UBT) at least 6 weeks after cessation of antimicrobial therapy. Intention-to-treat eradication rates were 78.2% (95%CI 69%-87%) with OAC1w and 88.4% (95%CI 81%-96%) with OAC2w. Per-protocol eradication rates were 86.0% (95% CI 78%-94%) with OAC1w, 97.0% (95%CI 93%-100%) with OAC2w. There was no significant difference in the eradication rates between OAC1w and OAC2w. Side effects were mild and self-limiting in both groups. In conclusion, both 1- and 2-week triple therapy with OAC are well tolerated and provide good eradication rates in peptic ulcer patients in Japan. The eradication rate of the 2-week regimen was higher than that of the 1-week regimen, but the difference was not statistically significant. Further studies including long-term economic considerations are required to determine the optimal duration of treatment. (author abst.)

Related Articles;